Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD70-targeting CAR-NK Cell Therapy for Refractory/Relapsed T Cell Lymphoma and Acute Myeloid Leukemia
NCT06696846Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2024
- Primary completion
- Nov 2027
- Modality
- Gene Editing, Gene Silencing, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD70 CAR-NK in T-cell lymphoma and acute myeloid leukemia (AML), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Dose-Limiting Toxicity at 28 days and Treatment-Related Adverse Events at 90 days. Started Dec 2024; status: recruiting.
02
Drugs
CD70 CAR-NK
03
Conditions
T-cell lymphomaacute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06696846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06696846.